Kailera Therapeutics, Inc. (KLRA)
KLRA Stock Price Chart
Explore Kailera Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze KLRA price movements and trends.
KLRA Company Profile
Discover essential business fundamentals and corporate details for Kailera Therapeutics, Inc. (KLRA) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
17 Apr 2026
Employees
145.00
Website
www.kailera.comCEO
Ronald C. Renaud Jr.
Description
Kailera Therapeutics is a biopharmaceutical company currently advancing through its clinical development stage, dedicated to cultivating a varied portfolio of cutting-edge treatments. These therapeutics are specifically engineered to tackle obesity and its associated metabolic disorders. The company distinguishes itself through its focus on innovative methodologies, offering both injectable and orally administered formulations for sustainable weight management. Its most advanced candidate is a groundbreaking dual-action gut hormone receptor agonist, which has reported encouraging outcomes in its initial clinical investigations.
KLRA Financial Timeline
Browse a chronological timeline of Kailera Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 25 Aug 2026
EPS estimate is -$0.76.
Earnings released on 26 May 2026
EPS came in at -$3.65k falling short of the estimated -$0.78 by -470.87k%.
KLRA Stock Performance
Access detailed KLRA performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
